Elite Pharmaceuticals (ELTP)
(Delayed Data from OTC)
$0.61 USD
0.00 (0.72%)
Updated Nov 5, 2025 03:30 PM ET
NA Value NA Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELTP 0.61 0.00(0.72%)
Will ELTP be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ELTP based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ELTP
Elite Pharma Stock Falls 32% Despite 52% Revenue Growth in FY2025
ELTP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELTP
Elite Pharmaceuticals EVP Sells Massive Stock Shares!
Q1 2026 Elite Pharmaceuticals Inc Earnings Call Transcript
Elite Pharmaceuticals Inc (ELTP) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Elite Pharmaceuticals GAAP EPS of -$0.01, revenue of $40.2M
Elite Pharmaceuticals Inc Reports Q1 FY2026 Earnings: Revenue Surges to $40. ...